ATE266031T1 - Verfahren und verbindungen zur behandlung proliferativer erkrankungen - Google Patents

Verfahren und verbindungen zur behandlung proliferativer erkrankungen

Info

Publication number
ATE266031T1
ATE266031T1 AT01972948T AT01972948T ATE266031T1 AT E266031 T1 ATE266031 T1 AT E266031T1 AT 01972948 T AT01972948 T AT 01972948T AT 01972948 T AT01972948 T AT 01972948T AT E266031 T1 ATE266031 T1 AT E266031T1
Authority
AT
Austria
Prior art keywords
compounds
methods
proliferative diseases
treating proliferative
formula
Prior art date
Application number
AT01972948T
Other languages
English (en)
Inventor
Thomas Albert Engler
Kelly Wayne Furness
Sushant Malhotra
Stephen Lyle Briggs
Harold Burns Brooks
David Keyes Clawson
Concepcion Sanchez-Martinez
Faming Zhang
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE266031T1 publication Critical patent/ATE266031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01972948T 2000-09-29 2001-09-24 Verfahren und verbindungen zur behandlung proliferativer erkrankungen ATE266031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23661600P 2000-09-29 2000-09-29
PCT/US2001/027728 WO2002028861A2 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
ATE266031T1 true ATE266031T1 (de) 2004-05-15

Family

ID=22890242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972948T ATE266031T1 (de) 2000-09-29 2001-09-24 Verfahren und verbindungen zur behandlung proliferativer erkrankungen

Country Status (10)

Country Link
US (1) US7109229B2 (de)
EP (1) EP1325011B1 (de)
AT (1) ATE266031T1 (de)
AU (1) AU2001292579A1 (de)
DE (1) DE60103171T2 (de)
DK (1) DK1325011T3 (de)
ES (1) ES2220811T3 (de)
PT (1) PT1325011E (de)
TR (1) TR200401316T4 (de)
WO (1) WO2002028861A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
DE602007006990D1 (de) 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate als antagonisten des via-rezeptors
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
CA2742790C (en) * 2008-11-19 2018-02-13 Cephalon, Inc. Novel forms of an indazolo[5,4-a]pyrrolo [3,4-c] carbazole compound
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
SG10201503541WA (en) * 2010-05-18 2015-06-29 Cephalon Inc Method for purifying a fused pyrrolocarbazole derivative
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
ME03557B (de) 2013-03-15 2020-07-20 G1 Therapeutics Inc Vorübergehender schutz von normalen zellen während einer chemotherapie
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (de) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217964A1 (de) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
WO2002028861A2 (en) 2002-04-11
EP1325011B1 (de) 2004-05-06
DE60103171D1 (de) 2004-06-09
US7109229B2 (en) 2006-09-19
WO2002028861A8 (en) 2003-11-20
DE60103171T2 (de) 2004-11-11
EP1325011A2 (de) 2003-07-09
DK1325011T3 (da) 2004-08-16
US20040048915A1 (en) 2004-03-11
TR200401316T4 (tr) 2004-07-21
AU2001292579A1 (en) 2002-04-15
WO2002028861A3 (en) 2002-08-01
ES2220811T3 (es) 2004-12-16
PT1325011E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
IL233053A0 (en) mek inhibitors and methods of using them
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE69940951D1 (de) Nd wachstumshemmende mittel
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60106947D1 (de) Oxindolderivate
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
ATE319709T1 (de) Indolderivate zur behandlung von depression und angstzuständen
DE602004030545D1 (de) Behandlung proliferativer erkrankungen mit epothilon-derivaten und bestrahlung
SG149051A1 (en) Nicotinic acetylcholine receptor ligands
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
SG149052A1 (en) Nicotinic acetylcholine receptor ligands
ATE293107T1 (de) Luminacine analoge und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1325011

Country of ref document: EP

REN Ceased due to non-payment of the annual fee